Taken together, these findings suggest that p-GSK-3β (Ser9) may be a useful biomarker for glioma development, and provide new information for using GSK-3β-based diagnostics and/or potential therapeutic target for glioma treatments in the future. Here, GSK3B is linked to glioma.